Søgning på udtrykket 'tixagevimab' giver 7 resultater


Nyt fra tidsskrifterne [6] Aktuelle smitsomme sygdomme [1]

Nyt fra tidsskrifterne [6]

Clinical Microbiology and Infection
31.07.2022
Immunocompromised patients have an increased risk of severe form of COVID-19. The clinical efficacy of the tixagevimab/cilgavimab monoclonal antibody combination as pre-exposure prophylaxis against BA.1 and BA.2 SARS-CoV-2 Omicron sublineages is unknown. We aimed to describe the incidence and outcomes of COVID-19 among immunocompromised patients receiving tixagevimab/cilgavimab as preexposure prophylaxis, during the Omicron wave in France.
New England Journal of Medicine
20.04.2022
New England Journal of Medicine, Ahead of Print.
Journal of the American Medical Association
25.01.2022
This Medical Letter review summarizes the use of tixagevimab and cilgavimab (Evusheld), investigational long-acting monoclonal antibodies to be administered concomitantly by intramuscular injection for preexposure prophylaxis of COVID-19 in persons aged 12 years or older.
Clinical Microbiology and Infection
31.07.2022
Immunocompromised patients have an increased risk of severe form of COVID-19. The clinical efficacy of the tixagevimab/cilgavimab monoclonal antibody combination as pre-exposure prophylaxis against BA.1 and BA.2 SARS-CoV-2 Omicron sublineages is unknown. We aimed to describe the incidence and outcomes of COVID-19 among immunocompromised patients receiving tixagevimab/cilgavimab as preexposure prophylaxis, during the Omicron wave in France.
Journal of the American Medical Association
26.07.2022
Tixagevimab plus cilgavimab, a SARS-CoV-2–neutralizing monoclonal antibody combination marketed as Evusheld, protected nonhospitalized individuals with mild to moderate COVID-19 symptoms from progressing to severe COVID-19 or death in a clinical trial. The study, published in The Lancet Respiratory Medicine, is the first to evaluate the intramuscular injection for outpatient treatment; other anti–SARS-CoV-2 monoclonal antibodies must be administered intravenously or subcutaneously.
Journal of the American Medical Association
25.01.2022
This Medical Letter review summarizes the use of tixagevimab and cilgavimab (Evusheld), investigational long-acting monoclonal antibodies to be administered concomitantly by intramuscular injection for preexposure prophylaxis of COVID-19 in persons aged 12 years or older.

Aktuelle smitsomme sygdomme [1]

Medscape Infectious Diseases
1.10.2021
Two long-acting antibodies — tixagevimab mixed with cilgavimab — reduced the risk of developing symptomatic COVID by 77% in a phase 3 trial of adults at high risk of contracting the virus.

Nyhedsbrev

Skriv din email adresse og modtag nyheder om hjemmesiden.


© 2022 Dansk Selskab for Infektionsmedicin

CVR: 33634307

version: 2.11.0 ● design: Christian Philip Fischer

Side indlæst på 0,568 s

Cookies og privatliv